News
Employee Screening for Controlled Substance Access: The Compliance Requirement Too Many Companies Take for Granted
In highly regulated pharmaceutical operations, companies invest significant time and resources into physical security, inventory controls, DEA registrations, and state licensing requirements. Yet one of the most important safeguards protecting controlled...
Why Every Pharmaceutical Company Needs More Than One Designated Representative
Imagine receiving notice that your facility's Designated Representative has resigned effective immediately. At first glance, it may seem like a standard personnel issue. Someone leaves, you hire a replacement, and business moves on. In the pharmaceutical...
FDA Registration Is Not a State Licensing Strategy: What Medical Device Companies Need to Know
For many medical device companies, regulatory compliance begins with the FDA. Establishment registration is completed. Device listings are maintained. Quality systems are implemented. From a federal perspective, the company appears well-positioned for...
Still Managing Your State Licensing Portfolio in Excel? There’s a Better Way.
For decades, Excel spreadsheets have been a staple of business operations. They are flexible, familiar, and capable of organizing vast amounts of information. Within pharmaceutical companies, spreadsheets have often become the default tool for tracking state...
The Regulatory Changes You Don’t See Can Cost You Everything
For pharmaceutical companies, maintaining state licenses is often viewed as a routine compliance obligation. Applications are filed, renewals are submitted, fees are paid, and business moves forward. At least that's how it works when everything goes according...
The Regulatory Shift Virtual Pharmaceutical Companies Can’t Ignore
States are rethinking how virtual manufacturers and wholesalers should be licensed. Is your compliance strategy keeping up? The pharmaceutical industry has embraced a business model that would have seemed almost impossible a generation ago. Today a company can...
The Real Risk of Managing a Pharmaceutical Change of Ownership
In the pharmaceutical industry, a Change of Ownership (CHOW) is far more than a business transaction. Whether a company is acquiring a facility, restructuring corporate ownership, merging operations, or transitioning to a new legal entity, the compliance implications...
The Compliance Risk Most Companies Don’t See Until It’s Too Late
In the pharmaceutical industry, compliance teams spend enormous amounts of time focused on evolving regulations, DSCSA obligations, inspections, and operational continuity. Yet one of the most common compliance risks often comes from something deceptively simple:...
NABP’s New DDA Requirements Just Raised the Bar for Compliance
For years, many organizations approached accreditation with a familiar mindset. Build a solid set of standard operating procedures, document where key requirements are addressed, and ensure everything is organized well enough to pass review. That approach is no longer...